paclitaxel has been researched along with Diabetic Angiopathies in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (49.12) | 29.6817 |
| 2010's | 28 (49.12) | 24.3611 |
| 2020's | 1 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| He, J; Hou, Z; Ouyang, H; Song, L; Tao, Z; Xie, S; Xu, J; Zeng, X; Zhang, C | 1 |
| Codner, P; Gurm, HS; Motivala, A | 1 |
| Hillegass, WB | 1 |
| Ahn, Y; Cho, HH; Hong, MH; Jeong, HY; Jeong, MH; Kang, WS; Kee, HJ; Kim, YS; Kwon, JS | 1 |
| Whitlow, P | 1 |
| Bangalore, S; Burke, DA; Cutlip, DE; Kandzari, DE; Leon, MB; Mauri, L; Pencina, MJ; Vardi, M | 1 |
| Angioli, P; Bellandi, G; Bolognese, L; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Porto, I; Ricci, L; Turini, F; Ventoruzzo, G | 3 |
| Cully, M | 1 |
| Boudriot, E; Dänschel, W; Desch, S; Erbs, S; Heinz, A; Kleinertz, K; Lauer, B; Linke, A; Schloma, D; Schuler, G; Stiermaier, T; Thiele, H | 1 |
| Bansilal, S; Mehran, R | 1 |
| Armstrong, EJ; Laird, JR | 1 |
| Hino, S; Ishikawa, T; Mutoh, M; Nakano, Y; Suzuki, T | 1 |
| Airoldi, F; Cetta, F; Clerici, G; Losa, S; Oberto, S; Rossi, F; Spirito, R; Tavano, D; Trabattoni, P; Zoli, S | 1 |
| Aerden, D; Debing, E; Gallala, S; Vanhulle, A; von Kemp, K | 1 |
| Akduman, EI; Altinbas, NK; Bilici, M; Oz, EB; Oz, II; Serifoglu, I | 1 |
| Christiansen, EH; Galloe, A; Hansen, HS; Hansen, KN; Jensen, LO; Joergensen, E; Kelbaek, H; Lassen, JF; Maeng, M; Mintz, GS; Thayssen, P; Thuesen, L | 1 |
| Agostoni, P; Van den Branden, F | 1 |
| Allemann, S; Cervinka, P; Chechi, T; De Carlo, M; de Lezo, JS; Diem, P; Dirksen, MT; Erglis, A; Goy, JJ; Jüni, P; Kastrati, A; Kelbaek, H; Leon, MB; Meier, B; Menichelli, M; Morice, MC; Ortolani, P; Park, SJ; Pfisterer, ME; Sabaté, M; Schalij, MJ; Schömig, A; Spaulding, C; Stettler, C; Stone, GW; Suttorp, MJ; Vermeersch, P; Wandel, S; Windecker, S | 1 |
| Christiansen, EH; Galloe, A; Hansen, KN; Jensen, LO; Kelbaek, H; Lassen, JF; Maeng, M; Thayssen, P; Thuesen, L | 1 |
| Legrand, V; Nyssen, A; Scheen, AJ | 1 |
| Byrne, RA; Di Lorenzo, E; Dibra, A; Iijima, R; Kaiser, C; Kastrati, A; Laarman, GJ; Mehilli, J; Menichelli, M; Ndrepepa, G; Schömig, A; Spaulding, C; Suttorp, MJ; Tierala, I; Valgimigli, M; Violini, R | 1 |
| Alonso-Briales, JH; de Teresa-Galván, E; Domínguez-Franco, AJ; Hernández-García, JM; Jiménez-Navarro, MF; Leruite-Martín, I; Linde-Estrella, AL; Olalla-Mercadé, E; Pérez-González, O | 1 |
| Fitzgerald, P; Kandzari, DE; Kirtane, AJ; Leon, MB; Mauri, L; McLaurin, B; O'Shaughnessy, C; Overlie, P; Patel, R; Popma, JJ; Solomon, S | 1 |
| Austin, PC; Blackhouse, G; Chiu, M; Cohen, EA; Goeree, R; Ko, DT; Tu, JV; Velianou, JL | 1 |
| Banning, AP; Berti, S; Dawkins, KD; Glauber, M; Kappetein, AP; Kellett, MA; Kramer, RS; Leadley, K; Mohr, FW; Morice, MC; Serruys, PW; Westaby, S | 1 |
| Abbott, JD; Anderson, WD; Holper, EM; Kelsey, SF; Kip, KE; Laskey, WK; Lee, JS; Marroquin, OC; Mulukutla, SR; Schindler, JT; Smith, C; Vlachos, HA; Williams, DO; Wolf, WM | 1 |
| Applegate, RJ; Cutlip, DE; Farhat, N; Kereiakes, DJ; Rizvi, A; Simonton, CA; Sood, P; Stone, GW; Su, G; Su, X; Sudhir, K; Wang, J; Yaqub, M | 1 |
| Bongo, AS; Buffon, A; De Servi, S; Lazzero, M; Lupi, A; Navarese, EP; Sansa, M; Serra, A | 1 |
| Airoldi, F; Biondi-Zoccai, G; Briguori, C; Caiazzo, G; Condorelli, G; Focaccio, A; Golia, B; Ricciardelli, B; Visconti, G | 1 |
| Brodie, BR; Dudek, D; Guagliumi, G; Hartmann, F; Hood, KL; Kornowski, R; Lansky, AJ; Mehran, R; Nikolsky, E; Parise, H; Peruga, JZ; Stone, GW; Witzenbichler, B; Wöhrle, J | 1 |
| Fahy, M; Kedhi, E; Kereiakes, DJ; Parise, H; Serruys, PW; Smits, PC; Stone, GW | 1 |
| Kastrati, A; Massberg, S; Ndrepepa, G | 1 |
| Briguori, C; de Waha, A; Dibra, A; Galloe, AM; Kastrati, A; Kim, MH; Kufner, S; Lee, SW; Lim, DS; Maeng, M; Park, SW; Schömig, A; Tomai, F | 1 |
| Barbash, IM; Hauville, C; Laynez, A; Pakala, R; Pichard, AD; Sardi, G; Satler, LF; Torguson, R; Waksman, R; Xue, Z | 1 |
| Bouchard, A; Guy, LG; Hsu, S; Lema, P; Polyakov, I; Savard, C; Sheehy, A; Tai, J | 1 |
| Gomes, ME; Harnek, J; James, S; Kedhi, E; Lagerqvist, B; Olivecrona, GK; Omerovic, E; Smith, JG | 1 |
| Bakhai, A; Leon, MB | 1 |
| Betge, S; Figulla, HR; Krack, A; Prochnau, D; Schwarz, G; Werner, GS | 1 |
| Finn, AV; Gold, HK; Kastrati, A; Palacios, IF | 1 |
| Cannon, L; Ellis, SG; Gurbel, PA; Hermiller, JB; Kutcher, MA; Mehran, R; Raizner, A; Russell, ME; Stone, GW; Wong, SC | 1 |
| Allemann, S; Diem, P; Egger, M; Meier, B; Stettler, C; Windecker, S | 1 |
| Boccara, F; Cohen, A; Teiger, E | 1 |
| Airoldi, F; Biondi-Zoccai, GG; Bonizzoni, E; Carlino, M; Chieffo, A; Colombo, A; Cosgrave, J; Melzi, G; Michev, I; Montorfano, M; Sangiorgi, GM | 1 |
| Dibra, A; Elezi, S; Folkerts, U; Heigl, S; Kastrati, A; Mehilli, J; Schömig, A | 1 |
| Alfonso, F; Angiolillo, DJ; Bass, TA; Cervinka, P; Corros, C; Costa, MA; Futamatsu, H; Hernandez-Antolin, R; Jiang, J; Jimenez-Quevedo, P; Macaya, C; Morikawa-Futamatsu, K; Sabaté, M | 1 |
| Briguori, C; Cabbavale, M; Pagnotta, P | 1 |
| Daemen, J; de Jaegere, PP; Garcia-Garcia, HM; Imani, F; Kukreja, N; Serruys, PW; Sianos, G; van Domburg, RT | 1 |
| Bruskina, O; Ibrahim, M; Iijima, R; Kastrati, A; Markwardt, C; Mehilli, J; Ndrepepa, G; Pache, J; Schömig, A | 1 |
| De Luca, L; Favero, L; Ferrero, V; Galassi, AR; Gaspardone, A; Ghini, AS; Gioffrè, G; Prati, F; Reimers, B; Ribichini, F; Tamburino, C; Tomai, F | 1 |
| Aliot, E; Angiol, M; Chodek-Hingray, A; Ethevenot, G; Lemoine, J; Moulin, F; Popovic, B | 1 |
| Barbagallo, R; Capranzano, P; Ciriminna, S; Fiscella, A; Galassi, AR; Grassi, R; Nicosia, A; Patti, A; Saccone, G; Stabile, A; Tagliareni, F; Tamburino, C; Tolaro, S; Ussia, G | 1 |
| Beutler, J; Billinger, M; Cook, S; Eberli, FR; Jüni, P; Lüscher, TF; Meier, B; Remondino, A; Seiler, C; Stettler, C; Taghetchian, KR; Togni, M; Wandel, S; Wenaweser, P; Windecker, S | 1 |
| Colombo, A; Dawkins, KD; Ellis, SG; Fahy, M; Grube, E; Kirtane, AJ; Leon, MB; Mehran, R; Moses, JW; Popma, JJ; Stone, GW | 1 |
| Bae, JH; Cha, KS; Chae, SC; Gwon, HC; Hong, SJ; Hur, SH; Kim, MH; Lim, DS; Park, HS | 1 |
| Chevalier, B; Dorange, C; Džavík, V; Grube, E; Guagliumi, G; Kaul, U; Papeleu, P; Smits, PC; Stuteville, M | 1 |
12 review(s) available for paclitaxel and Diabetic Angiopathies
| Article | Year |
|---|---|
A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients.
Topics: Cardiovascular Agents; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug-Eluting Stents; Everolimus; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Sirolimus; Treatment Outcome | 2021 |
Coronary Stents in Diabetic Patients: State of the Knowledge.
Topics: Coronary Disease; Diabetic Angiopathies; Drug-Eluting Stents; Everolimus; Humans; Immunosuppressive Agents; Paclitaxel; Sirolimus; Treatment Outcome | 2017 |
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.
Topics: Blood Vessel Prosthesis; Coronary Restenosis; Diabetic Angiopathies; Drug-Eluting Stents; Humans; Paclitaxel; Platelet Aggregation Inhibitors; Prosthesis Failure; Randomized Controlled Trials as Topic; Sirolimus; Stents | 2008 |
Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials.
Topics: Aged; Antineoplastic Agents, Phytogenic; Diabetic Angiopathies; Drug-Eluting Stents; Electrocardiography; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Randomized Controlled Trials as Topic; Sirolimus; Stents; Treatment Outcome | 2009 |
Drug-eluting stents vs. bare metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patients.
Topics: Aged; Aged, 80 and over; Angioplasty; Bias; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Coronary Restenosis; Diabetic Angiopathies; Drug-Eluting Stents; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Paclitaxel; Postoperative Complications; Randomized Controlled Trials as Topic; Regression Analysis; Saphenous Vein; Sirolimus; Stents; Treatment Outcome | 2011 |
Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Disease; Diabetic Angiopathies; Drug-Eluting Stents; Everolimus; Humans; Immunosuppressive Agents; Paclitaxel; Randomized Controlled Trials as Topic; Sirolimus; Tubulin Modulators | 2011 |
A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease.
Topics: Coronary Artery Disease; Diabetic Angiopathies; Drug-Eluting Stents; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Sirolimus | 2011 |
Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Coronary Restenosis; Diabetic Angiopathies; Humans; Paclitaxel; Platelet Glycoprotein GPIIb-IIIa Complex; Sirolimus; Stents | 2003 |
Drug-eluting stents for diabetes mellitus: a rush to judgment?
Topics: Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetic Angiopathies; Drug Delivery Systems; Humans; Paclitaxel; Sirolimus; Stents | 2005 |
Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials.
Topics: Blood Vessel Prosthesis; Coronary Restenosis; Diabetic Angiopathies; Drug Implants; Humans; Immunosuppressive Agents; Paclitaxel; Randomized Controlled Trials as Topic; Sirolimus; Stents | 2006 |
How to treat diabetic patients with multivesseal disease in the DES era.
Topics: Combined Modality Therapy; Coronary Artery Disease; Diabetic Angiopathies; Drug Delivery Systems; Humans; Immunosuppressive Agents; Paclitaxel; Sirolimus; Stents; Tubulin Modulators | 2006 |
Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retreatment; Risk Factors; Stents; Survival Analysis; Treatment Outcome | 2008 |
17 trial(s) available for paclitaxel and Diabetic Angiopathies
| Article | Year |
|---|---|
Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Agents; Coronary Artery Disease; Coronary Restenosis; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Risk Factors; Sirolimus; Time Factors; Treatment Outcome | 2013 |
Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Diabetic Angiopathies; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Ischemia; Knee; Leg; Limb Salvage; Male; Middle Aged; Paclitaxel; Prospective Studies; Secondary Prevention; Treatment Outcome; Tubulin Modulators | 2013 |
Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial).
Topics: Aged; Cardiovascular Agents; Coronary Artery Disease; Coronary Thrombosis; Diabetic Angiopathies; Drug-Eluting Stents; Female; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Polymers; Prospective Studies; Prosthesis Design; Risk Factors; Sirolimus; Time Factors; Treatment Outcome | 2014 |
Paclitaxel-coated versus plain old balloon angioplasty for the treatment of infrainguinal arterial disease in diabetic patients: the Belgian diabetic IN.PACT Trial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Belgium; Cardiovascular Agents; Coated Materials, Biocompatible; Diabetic Angiopathies; Equipment Design; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Intravascular ultrasound assessment of expansion of the sirolimus-eluting (cypher select) and paclitaxel-eluting (Taxus Express-2) stent in patients with diabetes mellitus.
Topics: Aged; Coronary Restenosis; Diabetes Mellitus; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Risk Factors; Sirolimus; Ultrasonography, Interventional | 2008 |
Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial.
Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Coronary Vessels; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Hyperplasia; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Sirolimus; Treatment Outcome; Tunica Intima; Ultrasonography | 2008 |
Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prospective Studies; Prosthesis Design; Severity of Illness Index; Single-Blind Method; Sirolimus; Time Factors; Treatment Outcome; United States | 2009 |
Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome; Tubulin Modulators | 2010 |
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Diabetic Angiopathies; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Prospective Studies; Sirolimus; Treatment Failure | 2010 |
Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Sirolimus | 2011 |
Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Male; Metals; Middle Aged; Myocardial Infarction; Paclitaxel; Prospective Studies; Stents; Treatment Outcome | 2011 |
Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Chronic Disease; Cohort Studies; Coronary Angiography; Coronary Disease; Coronary Restenosis; Diabetic Angiopathies; Female; Humans; Incidence; Male; Middle Aged; Paclitaxel; Secondary Prevention; Stents; Survival Analysis; Treatment Outcome | 2004 |
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
Topics: Antineoplastic Agents; Coronary Restenosis; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; Male; Middle Aged; Myocardial Revascularization; Paclitaxel; Polymers; Prospective Studies; Stents; Treatment Outcome | 2005 |
Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Coronary Angiography; Coronary Disease; Coronary Restenosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Sirolimus | 2008 |
Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Restenosis; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Male; Myocardial Revascularization; Paclitaxel; Sirolimus; Treatment Outcome; Tubulin Modulators | 2008 |
Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients.
Topics: Aged; Blood Vessel Prosthesis Implantation; Coronary Angiography; Coronary Stenosis; Diabetic Angiopathies; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Korea; Male; Middle Aged; Paclitaxel; Prospective Studies; Secondary Prevention; Sirolimus; Treatment Outcome | 2008 |
The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Eluting Stents; Europe; Evaluation Studies as Topic; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prospective Studies; Risk Assessment; Single-Blind Method; Sirolimus; Statistics, Nonparametric; Survival Analysis; Taxus; Treatment Outcome | 2012 |
28 other study(ies) available for paclitaxel and Diabetic Angiopathies
| Article | Year |
|---|---|
Diabetes and everolimus-eluting stents: good offense scores but defense wins tough games.
Topics: Cardiovascular Agents; Coronary Artery Disease; Diabetic Angiopathies; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Paclitaxel; Percutaneous Coronary Intervention; Sirolimus | 2013 |
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.
Topics: Administration, Oral; Angioplasty, Balloon; Animals; Aorta; Aortic Diseases; Apoptosis; Blood Glucose; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Drug-Eluting Stents; Endothelial Cells; Intercellular Adhesion Molecule-1; Male; Neovascularization, Pathologic; Paclitaxel; Phosphodiesterase 3 Inhibitors; Prosthesis Design; Rats; Rats, Sprague-Dawley; Tetrazoles; Thrombosis; Time Factors; Vascular Cell Adhesion Molecule-1; von Willebrand Factor; Wound Healing | 2013 |
Drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Coronary Disease; Coronary Restenosis; Diabetic Angiopathies; Drug-Eluting Stents; Humans; Immunosuppressive Agents; Paclitaxel; Sirolimus | 2004 |
Diabetes: Drug-eluting balloons for the treatment of critical limb ischaemia.
Topics: Angioplasty, Balloon; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Ischemia; Leg; Male; Paclitaxel | 2013 |
Polymer-free stents in diabetic patients-not so sweet after all!
Topics: Cardiovascular Agents; Coronary Artery Disease; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Percutaneous Coronary Intervention; Polymers; Sirolimus | 2014 |
Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Diabetic Angiopathies; Equipment Design; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Retreatment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome; Ultrasonography; Vascular Access Devices | 2014 |
Commentary: treatment of femoropopliteal in-stent restenosis for patients with diabetes: do we have an answer to the DEBATE?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Diabetic Angiopathies; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2014 |
Propensity score-matched lesion-based comparison of mid-term angiographic outcomes of TAXUS Liberté with Cypher Bx Velocity stents for de novo native coronary stenosis and in patients with diabetes.
Topics: Aged; Antineoplastic Agents; Coronary Angiography; Coronary Stenosis; Diabetes Complications; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Odds Ratio; Paclitaxel; Percutaneous Coronary Intervention; Propensity Score; Retrospective Studies; Sirolimus; Treatment Outcome | 2014 |
Comparison of SFA lesion treatment with Zilver PTX in diabetics vs. non-diabetics: 2-year clinical and functional results.
Topics: Aged; Aged, 80 and over; Alloys; Amputation, Surgical; Cardiovascular Agents; Diabetic Angiopathies; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Retreatment; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Constriction, Pathologic; Critical Illness; Diabetic Angiopathies; Drug-Eluting Stents; Female; Femoral Artery; Historically Controlled Study; Humans; Ischemia; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Registries; Retreatment; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
Comparison of Drug-Eluting Balloon and Standard Balloon Angioplasty for Infrapopliteal Arterial Diseases in Diabetic Patients.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Diabetic Angiopathies; Equipment Design; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Turkey; Vascular Access Devices; Vascular Patency | 2016 |
Drug eluting stents in patients with diabetes.
Topics: Coronary Restenosis; Diabetic Angiopathies; Drug-Eluting Stents; Humans; Meta-Analysis as Topic; Myocardial Revascularization; Paclitaxel; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sirolimus | 2008 |
[Benefit-risk ratio of coronary drug-eluting stents: 2nd part: evaluation in the diabetic population].
Topics: Coronary Artery Disease; Coronary Restenosis; Diabetic Angiopathies; Drug-Eluting Stents; Humans; Incidence; Paclitaxel; Postoperative Complications; Risk Assessment; Sirolimus; Thrombosis | 2008 |
Comparison of medium-term outcomes obtained with drug-eluting stents and coronary artery bypass grafts in an unselected population of diabetic patients with multivessel coronary disease. Propensity score analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Diabetic Angiopathies; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Immunosuppressive Agents; Logistic Models; Male; Middle Aged; Myocardial Revascularization; Paclitaxel; Retrospective Studies; Sirolimus; Treatment Outcome | 2009 |
Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Coronary Artery Disease; Diabetic Angiopathies; Disease-Free Survival; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Ontario; Paclitaxel; Proportional Hazards Models; Registries; Sirolimus; Tubulin Modulators | 2009 |
Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Diabetic Angiopathies; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; National Heart, Lung, and Blood Institute (U.S.); Paclitaxel; Prospective Studies; Registries; Sirolimus; United States | 2010 |
Is diabetes the achilles' heel of limus-eluting stents?
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Disease; Diabetic Angiopathies; Drug-Eluting Stents; Everolimus; Humans; Paclitaxel; Sirolimus | 2011 |
Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
Topics: Aged; Cardiovascular Agents; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Diabetic Angiopathies; Disease-Free Survival; District of Columbia; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Prosthesis Design; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.
Topics: Animals; Apoptosis; Cardiovascular Agents; Cells, Cultured; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Drug-Eluting Stents; Endothelial Cells; Everolimus; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Necrosis; Neointima; Paclitaxel; Percutaneous Coronary Intervention; Prosthesis Design; Sirolimus; Swine; Time Factors; Wound Healing | 2012 |
Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register.
Topics: Aged; Coronary Artery Disease; Diabetic Angiopathies; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Paclitaxel; Percutaneous Coronary Intervention; Prosthesis Design; Registries; Retrospective Studies; Sirolimus; Sweden | 2012 |
Role of drug eluting stents in diabetic patients.
Topics: Catheterization; Coronary Stenosis; Diabetic Angiopathies; Drug Implants; Humans; Immunosuppressive Agents; Paclitaxel; Sirolimus; Stents | 2006 |
Drug-eluting stent restenosis the pattern predicts the outcome.
Topics: Combined Modality Therapy; Coronary Restenosis; Diabetic Angiopathies; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Sirolimus; Stents | 2006 |
Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Disease; Coronary Restenosis; Cost Savings; Costs and Cost Analysis; Diabetic Angiopathies; Female; Germany; Health Services; Hospital Costs; Hospitalization; Humans; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Sirolimus | 2006 |
Characterization of plaque prolapse after drug-eluting stent implantation in diabetic patients: a three-dimensional volumetric intravascular ultrasound outcome study.
Topics: Aged; Chronic Disease; Coronary Disease; Coronary Stenosis; Diabetic Angiopathies; Drug Delivery Systems; Equipment Design; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Male; Metals; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Prolapse; Randomized Controlled Trials as Topic; Risk Assessment; Sirolimus; Stents; Treatment Outcome; Ultrasonography, Interventional | 2006 |
The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus.
Topics: Case-Control Studies; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drug Implants; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Retrospective Studies; Sirolimus; Stents; Survival Analysis | 2007 |
Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Coronary Restenosis; Coronary Thrombosis; Diabetic Angiopathies; Follow-Up Studies; Humans; Immunosuppressive Agents; Multivariate Analysis; Myocardial Infarction; Paclitaxel; Proportional Hazards Models; Risk Factors; Sirolimus; Stents; Survival Analysis; Treatment Outcome | 2007 |
[Long-term clinical benefits of using active stents in diabetic patients: two year follow-up of a consecutive series of 122 patients].
Topics: Aged; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Sirolimus; Survival Analysis; Treatment Outcome | 2007 |
Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Coronary Restenosis; Diabetic Angiopathies; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Registries; Sicily; Sirolimus | 2008 |